Last edition
News about
India's Pharma Industry Clocks INR 4.72 Lakh Crore Turnover in FY25: Economic Survey
India’s pharmaceutical industry delivered a strong performance in the financial year 2024–25, recording a total turnover of INR 4.72 lakh crore, according to the latest Economic Survey. The figures highlight the sector’s resilience and its growing role as a key contributor to India’s economy and global healthcare supply chain.
Phase II data show apecotrep, a first-in-class oral TRPC6 inhibitor, significantly reduced proteinuria in patients with primary FSGS, supporting ongoing Phase III development.
WuXi Biologics, Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases
WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development of SND006, a novel bispecific antibody targeting inflammatory bowel disease and autoimmune disorders.
FDA Grants Breakthrough Therapy Designation to Biogen's Litifilimab for Cutaneous Lupus
Biogen’s investigational monoclonal antibody litifilimab receives FDA Breakthrough Therapy designation, marking a major step toward targeted treatment for cutaneous lupus erythematosus.
QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer
ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.
Life Biosciences Wins FDA IND Clearance for ER-100
The IND clearance allows Life Bio to initiate a clinical programme evaluating ER-100’s safety and potential to improve vision in patients with optic neuropathies.
Cellares Moves Cell Therapy Manufacturing from Platform to Patients
The cell and gene therapy (CGT) sector is entering a phase of more disciplined and sustainable growth after years of volatility, according to industry leaders speaking at the 2026 Biotech Showcase in San Francisco.
Eli Lilly Enters USD 1.12 Billion Gene-Editing Partnership with Seamless Therapeutics
Eli Lilly and Company has entered into a strategic collaboration worth up to USD 1.12 billion with private gene-editing company Seamless Therapeutics to develop next-generation therapies for hearing loss. The agreement strengthens Lilly’s push into genetic medicines and expands its pipeline beyond its core diabetes and obesity treatments.
Immix Biopharma Gets US FDA Breakthrough Therapy Designation for NXC-201
Immix Biopharma has received US FDA Breakthrough Therapy Designation for its CAR-T candidate NXC-201, based on positive interim phase-II results from the NEXICART-2 study presented at the ASH 2025 annual meeting, with final data expected later this year followed by a planned Biologics Licence Application (BLA) submission.
Boehringer and Simcere Partner on Dual-Target IBD Antibody
Boehringer Ingelheim has signed a licence and collaboration deal with Simcere to develop a novel TL1A/IL23p19 bispecific antibody for inflammatory bowel disease, gaining global rights outside greater China, with Simcere eligible for up to €1.058 billion in payments.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy